If you have been reading about mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
====== Latin America ====== Drug war policies in Latin America and the Caribbean have led to more violence, higher incarceration rates, health crises, and deeper poverty, while undermining trust in institutions and worsening inequality. There is increasing support for shifting toward drug policies that focus on sustainable development and human rights instead of punitive measures.
In 1996, it became a contract research organization (CRO) for the biopharmaceutical sector and entered into collaboration with SmithKline Beecham biologicals (Rixensart, Belgium) for the production of recombinant proteins for phase I, II and III clinical trials. In addition to its pharmaceutical manufacturing activities, Eurogentec became a service company for the biotechnical research industry and university laboratories. In 1999, Eurogentec acquired Oswel Research Product Ltd. a biotechnology company based in Southampton, Great Britain and specialized in the synthesis of chemically modified and complex oligonucleotides and their analogues (DNA, RNA, PNA). In 2002, Eurogentec acquired Wita Proteomics, a company specialized in proteomics services, based in Berlin (Germany). A few months later, Eurogentec installed its US office in San Diego for the production of oligonucleotides (EGT NA).
=== Pharmacodynamics === Gabapentinoids are high affinity ligands of the α2δ protein that was first described as an auxiliary subunit of certain voltage-gated calcium channels (VGCC). All of the known pharmacological actions of gabapentinoids require binding at this site. There are two drug-binding α2δ subunits, α2δ-1 and α2δ-2, and most gabapentinoids show similar affinity for (and hence lack of selectivity between) these two sites. In most cases, gabapentinoid drugs do not seem to directly alter the action of VGCC and instead reduce the release of certain excitatory neurotransmitters. (However, see). The gabapentinoid drugs do not bind significantly to other known drug receptors and so the α2δ VGCC subunit has been called the gabapentin receptor. Recently, the same α2δ-1 protein has been found closely associated not with VGCCs but with other proteins such as presynaptic NMDA-type glutamate receptors, cell adhesion molecules such as thrombospondin and others. Gabapentinoids alter the function of these additional α2δ binding proteins, and these have been proposed as mediators of drug actions. Despite the fact that gabapentinoids are GABA analogues, gabapentin and pregabalin do not bind to GABA receptors, do not convert into GABATooltip γ-aminobutyric acid or GABA receptor agonists in vivo, and do not modulate GABA transport or metabolism. Conversely, GABA does not bind appreciably to the α2δ protein. Furthermore, gabapentinoids do not act directly as inhibitors or blockers of VGCC.
Sources: en.wikipedia.org
In 1942, anatomist Edward Congdon also demonstrated that the right and left mesocolons persisted into adulthood and remained separate from the retroperitoneum—extraretroperitoneal. Radiologist Wylie J. Dodds described this concept in 1986. Dodds extrapolated that unless the mesocolon remained an extraretroperitoneal structure—separate from the retroperitoneum—only then would the radiologic appearance of the mesentery and peritoneal folds be reconciled with actual anatomy. Descriptions of the mesocolon by Toldt, Congdon, and Dodds have largely been ignored in mainstream literature until recently. A formal appraisal of the mesenteric organ anatomy was conducted in 2012; it echoed the findings of Toldt, Congdon, and Dodds. The single greatest advance in this regard was the identification of the mesenteric organ as being contiguous, as it spans the gastrointestinal tract from duodenojejunal flexure to mesorectal level. In 2012 it was discovered that the mesentery was a single organ, which precipitated advancement in colon and rectum surgery and in sciences related to anatomy and development.
Jameson's mamba (Dendroaspis jamesoni) is known to be quite aggressive and defensive. The average venom yield per bite for this species is 80 mg, but some specimens may yield as much as 120 mg in a single bite. The SC LD50 for this species according to Brown (1973) is 1.0 mg/kg, while the IV LD50 is 0.8 mg/kg. Envenomation by Jameson's mamba can be deadly in as little as 30 to 120 minutes after being bitten, if proper medical treatment is not attained. The mortality rate of untreated bites is not exactly known, but it's said to be very high (>80%).
=== Personal guard of Prince Menelik === The Mehal Sefari's earlier roles were providing security for young Prince Menelik under the leadership of the later Dejazmach Germame. Upon the death of Atse Tewodros, 3 men – Wagshum Gobeze of Welo, Kassa Mircha of Tigre and Menelik of Shoa – were declared Atse. Kassa marched on Welo, defeated and imprisoned Gobeze, he marched south to Shewa to face Menelik who had gathered his forces and awaited him. Both rulers assumptive, Yohannes by virtue of arms left for him by the British and Menelik by blood sought reconciliation, Menelik agreeing to accept Yohannes as his Suzerain, much to the relief of the latter whose small, though well-armed forces were no match for the Shewan Army. Menelik's Army, though with fewer artillery pieces, had superiority in men, equipment and mounted cavalry. It would also have been fighting on home turf. Yohannes' spy sent to observe the Shoans is said to have come back to tell the Emperor "I thought clouds had descended on the ground, but it was the Shoans and their multitudes in their tents." Atse Menelik took this opportunity to continue to arm and train his men, dispatching men to the South and West in poses of providing security for the Emperor of Ethiopia and an elite infantry division.
Sources: en.wikipedia.org
Film has been the most influential medium in the presentation of the history of slavery to the general public around the world. The American film industry has had a complex relationship with slavery and until recent decades often avoided the topic. Films such as The Birth of a Nation (1915) and Gone with the Wind (1939) became controversial because they gave a favourable depiction. In 1940 The Santa Fe Trail gave a liberal but ambiguous interpretation of John Brown's attacks on slavery. The Civil Rights Movement in the 1950s made defiant slaves into heroes. The question of slavery in American memory necessarily involves its depictions in feature films. Most Hollywood films used American settings, although Spartacus (1960), dealt with an actual revolt in the Roman Empire known as the Third Servile War. The revolt failed, and all the rebels were executed, but their spirit lived on according to the film. Spartacus stays surprisingly close to the historical record. The Last Supper (La última cena in Spanish) was a 1976 film directed by Cuban Tomás Gutiérrez Alea about the teaching of Christianity to slaves in Cuba, and emphasizes the role of ritual and revolt. Burn! takes place on the imaginary Portuguese island of Queimada (where the locals speak Spanish) and it merges historical events that took place in Brazil, Cuba, Santo Domingo, Jamaica, and elsewhere.
== Finance minister == FinanceAsia for the second year running has ranked the finance ministers of the Asia-Pacific region's 12 largest economies. In the 2016 ranking, Thailand's Apisak Tantivorawong was ranked 11th (1=best, 12=worst). Ranked worst was Malaysia's Najib Razak.
== Career == She completed her secondary education at the Reformed College of Debrecen, graduating in 1971. She earned her medical degree summa cum laude from the University of Debrecen Medical School in 1977. Between 1977 and 1982, she worked at the Department of Anatomy, Histology and Embryology of the University of Debrecen Medical School. Then, from 1982 to 1993, she was a staff member of the Department of Clinical Chemistry. She held research fellowships at the State University of New York (1988), Thomas Jefferson University in Philadelphia (1989–1990), and Gifu University in Japan (1992). She obtained the Doctor of the Hungarian Academy of Sciences (D.Sc.) degree in 1992. In 1993, she was appointed full professor and director of the Department of Public Health and Epidemiology (later the Department of Preventive Medicine), a position she held until 2017. From 2005 to 2012 she served as the founding dean of the Faculty of Public Health at the University of Debrecen, and between 2007 and 2013 she was the vice-president responsible for medical specialization and postgraduate training of the Medical and Health Science Centre. From 2021 to 2024, she was a visiting professor at Semmelweis University and senior adviser to the Epidemiology and Surveillance Centre. Since November 2024, she has been a professor at the Institute of Preventive Medicine and Public Health of Semmelweis University.
=== Acidity === The C9–H sites of the fluorene ring are weakly acidic (pKa = 22.6 in DMSO). Deprotonation gives the stable fluorenyl anion, nominally C13H−9, which is aromatic and has an intense orange colour. The anion is a nucleophile. Electrophiles react with it by adding to the 9-position. The purification of fluorene exploits its acidity and the low solubility of its sodium derivative in hydrocarbon solvents. Both protons can be removed from C9. For example, 9,9-fluorenyldipotassium can be obtained by treating fluorene with potassium metal in boiling dioxane.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.